Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 4.7% - Should You Sell?

Key Points

• Capricor Therapeutics shares fell 4.7% to $9.43 in thin trading, with volume down 84% from the average session. The stock is well below its 50-day and 200-day moving averages.
• The FDA extended its review of deramiocel, offering additional time in the regulatory process, while Piper Sandler upgraded the stock. However, multiple securities lawsuits allege investors were misled about deramiocel and the HOPE-3 trial.
• Analyst sentiment is broadly cautious: the consensus rating is “Hold,” despite a $29.15 average price target. Capricor also missed quarterly EPS estimates, and insiders have sold roughly $759,000 of shares over the past three months.

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) fell 4.7% during mid-day trading on Thursday . The company traded as low as $9.36 and last traded at $9.43. 486,023 shares traded hands during trading, a decline of 84% from the average session volume of 3,063,639 shares. The stock had previously closed at $9.89.

Capricor Therapeutics News Summary

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Analyst upgrade and FDA review extension provide support. Piper Sandler upgraded Capricor, while reports highlighted that the FDA extended its review of deramiocel. The extension keeps the regulatory process active and may give the company additional time to address outstanding questions regarding the treatment for Duchenne muscular dystrophy complications. Capricor Therapeutics Shares Rise After Piper Sandler Upgrade
• Neutral Sentiment: Investors have until September 28, 2026, to seek lead-plaintiff status. Numerous law firms reiterated that shareholders who purchased CAPR securities generally between December 17, 2025, and July 26, 2026, may seek appointment as lead plaintiff in the pending federal class action. These announcements are procedural and do not establish wrongdoing or guarantee investor recovery. CAPR Investor Deadline Class Action Notice
• Negative Sentiment: Multiple securities lawsuits allege Capricor misled investors about deramiocel and the HOPE-3 trial. The complaints reportedly focus on alleged deviations from prespecified blinding, study-protocol and statistical-analysis procedures, as well as alleged misrepresentations about the path to FDA approval. The litigation follows FDA briefing documents associated with an alleged decline of approximately $15.08 per share and could create legal costs, reputational damage and additional regulatory uncertainty. CAPR Securities Class Action Deadline Alert

Analysts Set New Price Targets

CAPR has been the topic of a number of research reports. JonesTrading cut Capricor Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, July 31st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. Wall Street Zen lowered Capricor Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 1st. B. Riley Financial cut Capricor Therapeutics from a "buy" rating to a "neutral" rating and set a $10.00 price target for the company. in a research report on Monday, July 27th. Finally, Maxim Group lowered Capricor Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, July 30th. Three investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $29.15.

Capricor Therapeutics Trading Down 5.7%

The firm has a market capitalization of $542.21 million, a PE ratio of -3.81 and a beta of 0.72. The firm has a 50-day moving average of $13.29 and a two-hundred day moving average of $24.00.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.11). Equities research analysts expect that Capricor Therapeutics, Inc. will post -1.72 earnings per share for the current fiscal year.

Insider Transactions at Capricor Therapeutics

In related news, CFO Anthony Bergmann sold 24,100 shares of the firm's stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total value of $732,158.00. Following the transaction, the chief financial officer owned 11,223 shares in the company, valued at approximately $340,954.74. This trade represents a 68.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 25,000 shares of company stock worth $759,158. 9.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Capricor Therapeutics

Large investors have recently made changes to their positions in the business. Suvretta Capital Management LLC purchased a new stake in Capricor Therapeutics during the 4th quarter worth $51,533,000. Tang Capital Management LLC purchased a new position in Capricor Therapeutics in the fourth quarter valued at about $49,062,000. RA Capital Management L.P. acquired a new position in shares of Capricor Therapeutics during the fourth quarter worth about $43,516,000. California State Teachers Retirement System boosted its position in shares of Capricor Therapeutics by 2,261.8% in the second quarter. California State Teachers Retirement System now owns 1,528,478 shares of the biotechnology company's stock worth $36,806,000 after buying an additional 1,463,762 shares during the period. Finally, Darwin Global Management Ltd. purchased a new stake in shares of Capricor Therapeutics in the fourth quarter worth about $23,168,000. Institutional investors and hedge funds own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source